Song Sanghyuk, Chie Eui Kyu, Kim Kyubo, Lee Hyuk-Joon, Yang Han-Kwang, Han Sae-Won, Oh Do-Youn, Im Seock-Ah, Bang Yung-Jue, Ha Sung W
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Radiat Oncol J. 2012 Dec;30(4):213-7. doi: 10.3857/roj.2012.30.4.213. Epub 2012 Dec 31.
To evaluate treatment outcome of patients with high risk locally advanced gastric cancer after postoperative chemoradiotherapy.
Between May 2003 and May 2012, thirteen patients who underwent postoperative chemoradiotherapy for gastric cancer with resection margin involvement or adjacent structure invasion were retrospectively analyzed. Concurrent chemotherapy was administered in 10 patients. Median dose of radiation was 50.4 Gy (range, 45 to 55.8 Gy).
The median follow-up duration for surviving patients was 48 months (range, 5 to 108 months). The 5-year overall survival rate was 42% and the 5-year disease-free survival rate was 28%. Major pattern of failure was peritoneal seeding with 46%. Locoregional recurrence was reported in only one patient. Grade 2 or higher gastrointestinal toxicity occurred in 54% of the patients. However, there was only one patient with higher than grade 3 toxicity.
Despite reported suggested role of adjuvant radiotherapy with combination chemotherapy in gastric cancer, only very small portion of the patients underwent the treatment. Results from this study show that postoperative chemoradiotherapy provided excellent locoregional control with acceptable and manageable treatment related toxicity in patients with high risk locally advanced gastric cancer. Thus, postoperative chemoradiotherapy may improve treatment result in terms of locoregional control in these high risk patients. However, as these findings are based on small series, validation with larger cohort is suggested.
评估局部晚期高危胃癌患者术后放化疗的治疗效果。
回顾性分析2003年5月至2012年5月间13例行胃癌术后放化疗的患者,这些患者存在手术切缘受累或邻近结构侵犯情况。10例患者接受了同步化疗。放疗中位剂量为50.4 Gy(范围45至55.8 Gy)。
存活患者的中位随访时间为48个月(范围5至108个月)。5年总生存率为42%,5年无病生存率为28%。主要失败模式为腹膜种植,占46%。仅1例患者出现局部区域复发。54%的患者发生2级或更高等级的胃肠道毒性。然而,只有1例患者毒性高于3级。
尽管有报道称辅助放疗联合化疗在胃癌治疗中具有一定作用,但接受该治疗的患者比例非常小。本研究结果表明,术后放化疗在局部晚期高危胃癌患者中提供了良好的局部区域控制,且治疗相关毒性可接受且易于管理。因此,术后放化疗可能会改善这些高危患者在局部区域控制方面的治疗效果。然而,由于这些发现基于小样本系列研究,建议用更大队列进行验证。